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Abstract
Heart disease affects millions worldwide and is a progressive condition involving loss of
cardiomyocytes. The human heart has limited endogenous regenerative capacity and is thus an
important target for novel regenerative medicine approaches. While cell-based regenerative
therapies hold promise, cellular reprogramming of endogenous cardiac fibroblasts, which
represent more than half of the cells in the mammalian heart, may be an attractive alternative
strategy for regenerating cardiac muscle. Recent advances leveraging years of developmental
biology point to the feasibility of generating de novo cardiomyocyte-like cells from terminally
differentiated non-myocytes in the heart in situ after ischemic damage. Here, we review the
progress in cardiac reprogramming methods and consider the opportunities and challenges that lie
ahead in refining this technology for regenerative medicine.
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Cardiomyocyte death is associated with diverse forms of heart disease, which is the leading
cause of morbidity and mortality in industrialized countries. Myocardial infarctions (MI) are
a major public health problem and affect more than 1 million Americans yearly. A
tremendous loss of cardiomyocytes through apoptosis and/or necrosis underlies both acute
and chronic MI. To compensate for the death of cardiomyocytes in the injured area, scar
tissue is formed by activated fibroblasts. In addition, heart diseases related to pressure
overload, such as hypertension or valvular disease, involve the death of cardiac muscle cells
but the progression is slow and usually occurs over a long period of time. Human aging is
associated with an irreversible loss of cardiomyocytes, which may account for the increased
vulnerability of aged hearts to various risk factors1.
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Unlike amphibian and fish hearts2, the human heart has limited regenerative potential.
Although postnatal vertebrate cardiomyocytes undergo some degree of cell renewal, as
suggested by transgenic mouse experiments3-5and a more recent human radiocarbon dating
study6, the rate of cardiomyocyte renewal is very low. Agenetic fate map study in mice
indicated that the endogenous regenerative capacity of the adult heart, albeit limited, largely
comes from the differentiation of cardiac progenitor cells rather than replacement by
existing cardiomyocytes through cell division7, 8. A major challenge moving forward is to
identify such cardiac progenitor pools in the adult heart and promote their expansion and
differentiation potential in vivo. In contrast, Porrello et al. reported the neonatal mouse heart
has a remarkable regenerative capacity within the first 7 days of life, similar to that of the
zebrafish heart9. Genetic fate mapping suggests that myocyte proliferation is the main
mechanism for this regeneration9, which is reminiscent of what has been found in the adult
zebrafish heart10, 11. Furthermore, in a recent report using stable isotope labeling with
genetic fate-mapping in combination with multi-isotope imaging mass spectrometry, the
authors concluded that pre-existing CMs are the dominant source of myocyte renewal in the
adult mouse heart with or without injury5. Cardiomyocyte proliferation has been reported to
be enhanced by overexpressing cyclinD212, 13 or administering factors, such as Periostin14,
fibroblast growth factor-1 (FGF-1)15 or neuregulin 1 (NRG1)16 in mouse models of MI.
Most recently, addition of miR-199a and miR-590 also stimulated cardiomyocyte
proliferation in vitro and in vivo17. Thus, there is increasing evidence that adult mammalian
cardiomyocytes have the capacity to proliferate, but whether approaches to enhance this
feature are sufficient to compensate for the functional loss of damaged myocardium awaits
confirmation.
Another strategy to repair an injured heart is to supply new cardiomyocytes differentiated
from multipotent cardiovascular progenitor cells (CPCs) or pluripotent stem cells, including
embryonic stem (ES) cells and induced pluripotent stem (iPS) cells (reviewed extensively
elsewhere18-21). Cardiomyocytes derived from pluripotent stem cells are a promising source
of cells due to recent advances in efficiency of human cardiomyocyte differentiation.
However, the poor survival, low maturational efficiency, and limited functional integration
of engrafted cells are hurdles that must still be overcome. Introduction of adult progenitor
cells in animal models has positive effects after MI, but the cells do not appear to persist,
pointing to a potential paracrine effect (reviewed in 22, 23). Clinical trials are underway to
evaluate efficacy, with mixed results to date24.
Here, we will review a newly emerging strategy for cardiac regeneration that involves
reprogramming the vast pool of non-myocytes in the heart into new cardiomyocytes25. This
approach builds on recent cellular programming knowledge26 and leverages over 15 years of
advances in cardiac developmental biology20 to induce a cardiomyocyte-like fate in the
adult heart. Cardiac reprogramming can be induced by a discrete set of factors but appears to
have critical epigenetic blocks in vitro which are significantly overcome upon
reprogramming of cells in their native environment in vivo25, 27-30.We will review how
advances in cellular reprogramming and developmental biology led to our more recent work
in direct cardiac reprogramming and will consider the future potential of this rapidly
evolving approach to cardiac regeneration.
Cellular reprogramming
For decades, the concept in the field of developmental biology had been that cells, once
terminally differentiated, were relatively fixed in their cell fate. This dogma was first
challenged in the 1960s by the observation that a somatic cell can obtain totipotency through
nuclear transfer into an enucleated frog egg31. Cloning of Dolly the sheep in 1997 by
nuclear transfer revealed that the mammalian egg also had similar ability in reprogramming
Qian and Srivastava Page 2













an adult nucleus to the embryonic state32. In the late 80s and 90s, further evidence suggested
that cell fate conversion can take place by a more direct route. Blau and colleagues
demonstrated that fusion of skeletal muscle cells with fibroblasts resulted in heterokaryons
that induced conversion of fibroblasts into a skeletal muscle–like phenotype33. Studies from
the Weintraub lab subsequently demonstrated that fibroblasts could be converted into
skeletal muscle cells in vitro with forced expression of the skeletal muscle “master
regulator” gene MyoD, which encodes a basic helix-loop-helix domain-containing
transcription factor34, 35. Despite the race to identify individual transcription factors that
could function to guide cell fate similar to MyoD for other lineages, including
cardiomyocytes, the MyoD paradigm appeared to be an exception, rather than the rule.
Meanwhile, studies in model organisms showed that forced expression of individual master
regulatory transcription factors containing homeobox domains could induce formation of
complex body structures, which is best exemplified by the induction of ectopic eye
formation on the legs of Drosophila by overexpressing eyeless, the fly orthologue of Pax636.
The concept of cell fate conversion bypassing normal developmental lineage progression
therefore emerged, but was still largely neglected with respect to the application of such
concepts in regenerative medicine.
Takahashi and Yamanaka's milestone publication in 2006 demonstrating the creation of
induced pluripotent stem cells (iPSCs)37 ushered in a new era of utilizing cellular
reprogramming in regenerative medicine38-40. Co-expression of four transcription factors
(Oct4, Sox2, Klf4, c-Myc) was sufficient to reprogram fibroblasts to pluripotent stem cells
that had the potential to develop into viable animals41, 42. Abundant evidence has
demonstrated that iPSCs can be differentiated efficiently into multiple cell types that
someday could be used for regenerative therapies, disease modeling and drug discovery. A
key lesson from iPSC reprogramming was the recognition that a combinatorial code
involving a discrete number of regulatory factors could be sufficient to induce cell fate
change43, 44.
Despite the difficulty of identifying MyoD-like factors for direct cellular reprogramming
from one terminally differentiated adult somatic cell directly into another without taking a
“detour” back to pluripotency, the iPSC experience raised the possibility of a combination of
regulators that could together induce cell fate change, or transdifferentiation. This
reprogramming strategy was first demonstrated by Zhou et al., who directly converted
exocrine pancreatic cells into insulin-producing endocrine cells in the mouse pancreas with
the transcription factors, Ngn3, Pdx and Mafa45. Similarly, we showed that cardiac and
dermal fibroblasts could be reprogrammed into cardiomyocyte-like cells by a combination
of three transcription factors, Gata4, Mef2c, and Tbx25, 27. The direct reprogramming of
adult fibroblasts to neuronal-like cells was also achieved in vitro with forced expression of a
combination of transcription factors46, 47 or microRNAs (miRNAs)48, and similar
observations were made for conversion to the hepatocyte lineage49, 50. Unlike direct
reprogramming with multiple factors, Szabo et al. showed that combining expression of
only Oct4 with administration of select cytokines can reprogram human fibroblasts into
hematopoietic progenitors51, while transient expression of iPSC reprogramming factors,
followed by Jak/Stat inhibition, resulted in emergence of cardiomyocytes52. The advances in
cardiac reprogramming are considered in more detail below.
Discovery of transcription factor-based direct cardiac reprogramming
Over the last 20 years, developmental biology studies have revealed complex and
intertwined networks of signaling pathways, transcription factors and miRNAs that regulate
formation and function of the heart20, 53, 54. The networks are self-reinforcing with layers of
positive and negative feedback loops. Transcription factors often function in common
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complexes, and human mutations that disrupt their interaction can lead to similar forms of
heart malformations, as seen with mutations in GATA4 and TBX555. In 2009, Takeuchi and
Bruneau demonstrated that overexpression of Gata4, Tbx5 and the interacting chromatin
remodeling protein, Baf60c, converts noncardiogenic mesoderm into beating
cardiomyocytes in the embryo by a mechanism involving the induction of Nkx2-5 by Gata4
and Baf60c56.
The adult heart has many cell types within the organ that are normally non-cardiogenic. The
vast majority of these are cardiac fibroblasts, which comprise over 50% of cells in the heart
and are derived from an extracardiac structure known as the proepicardial organ57.
Fibroblasts play an important structural and paracrine role supporting the neighboring
myocytes58. Upon injury, cardiac fibroblasts are activated and migrate to the site of injury to
create scar tissue that replaces dead myocardium. Due to the abundance of resident cardiac
fibroblasts, the ability to reprogram such cells in situ would represent a powerful approach
for regenerating myocardium.
We leveraged the abundant knowledge of cardiac developmental biology to attempt
reprogramming of adult somatic cells into cardiomyocyte-like cells25. Despite the desire to
ultimately reprogram in vivo, we established an in vitro assay to discover the minimal
cocktail of factors that could convert non-cardiomycytes in the heart into a more
cardiomyocyte-like phenotype. We generated transgenic mice containing the EGFP reporter
downstream of the cardiomyocyte-specific αMHC (Myh6) promoter59 and isolated the
EGFP-negative non-myocyte population, which consisted largely of fibroblasts. Upon
retroviral introduction of 14 transcription factors, and a pool of miRNAs, neonatal αMHC-
EGFP– cells activated the expression of αMHC (Myh6) and the αMHC-EGFP reporter,
which allowed quantitative analysis by fluorescence activated cell sorting (FACS). The
miRNAs in this setting were dispensable. Through serial deletion of one transcription factor
at a time, we narrowed the required reprogramming factors to three: Gata4, Mef2c and Tbx5
(GMT). The GMT cocktail was sufficient to induce GFP expression in about 15–20% of the
cells, which we termed induced cardiomyocytes (iCMs). However, the vast majority of cells
were partially reprogrammed, with 5% of the total infected cell population expressing
additional cardiac markers, such as cTnT, and assembling sarcomeric structures;
furthermore, only ~0.5% of the αMHC−EGFP+/cTnT+ cells were capable of beating.
Despite the low percentage of fully reprogrammed cardiomyocytes, genome-wide
transcriptome studies of the αMHC−EGFP+ cells (~15% of infected cells) showed that the
partially reprogrammed population induced a broad cardiac transcriptional program
involving thousands of genes and also silenced the fibroblast transcriptome. Moreover, the
epigenetic status of iCMs was similar to neonatal endogenous cardiomyocytes at loci
examined, and the reprogramming event was stable, not requiring ongoing expression of
GMT. Notably, the GMT cocktail also reprogrammed tail-tip dermal fibroblasts, albeit with
lower efficiency, suggesting that the presence of a cardiac progenitor pool was not necessary
for the presence of iCMs.
Interestingly, the more fully reprogrammed iCMs had action potentials that were most
similar to adult ventricular myocytes. This observation was in contrast to the relatively
immature electrical activity noted in ES- or iPS-derived cardiomyocytes. Using a Cre-based
strategy, we found that iCMs never expressed Mesp1 or Isl1, markers of early cardiac
progenitors, during the process of cardiac reprogramming25. This suggested that the
reprogramming event represented a direct conversion from one adult cell type to another
rather than traversing through a progenitor stage. The rapidity of initial conversion and the
more mature electrophysiology observed in iCMs is consistent with this interpretation.
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In vivo direct cardiac reprogramming
The relatively poor quality and low efficiency of in vitro cardiac reprogramming might be
due to the lack of a natural environment for cardiomyocytes on plastic dishes. Because the
objective with this strategy was to harness the endogenous cardiac fibroblasts within the
organ for regeneration without needing to use cell-based therapy, we attempted to deliver
GMT in vivo after ischemic injury and convert non-myocytes to cardiomyocyte-like cells.
Classic genetic lineage tracing studies with Periostin-Cre, Fsp1-Cre and αMHC-MerCreMer
were performed to demonstrate that dividing non-myocytes infected by retroviruses could be
converted into iCMs27 over a period of 4 weeks. Careful studies demonstrated that the
newly born myocytes arose from in vivo conversion rather than leaky Cre expression or cell-
cell fusion. Importantly, intermediate stages of reprogramming to iCMs were identified and
characterized at varying time points after retroviral infection, further supporting the idea of a
progressive reprogramming process.
In vivo-derived iCMs developed many characteristics of endogenous CMs. They were bi-
nucleate, assembled sarcomeres and had cardiomyocyte-like gene expression by 4 weeks
post-infection with GMT. Furthermore, single-cell analyses by patch clamp technology
revealed that 50% of in vivo-derived iCMs closely resembled endogenous CMs with beating
upon electrical stimulation and ventricular cardiomyocyte-like action potentials. The
markedly improved quality of reprogramming in vivo compared to in vitro might have been
due to signals from the microenvironment, exposure to the extracellular matrix, or the
influence of mechanical forces while reprogramming. Importantly, we found evidence for
electrical coupling of the in vivo reprogrammed iCMs with endogenous cardiomyocytes and
other iCMs. In vivo delivery of GMT intramyocardially decreased scar size and attenuated
cardiac dysfunction after coronary ligation, as assessed by MRI and echocardiography. As
expected, the cardiomyocytes within the scar area of GMT-treated mice represented newly
born iCMs as determined by lineage tracing experiments. The beneficial effects of GMT
were enhanced with the addition of the pro-angiogenic and fibroblast-activating factor,
Thymosin β4, which independently promotes cardiac repair60, 61.
In a similar study, Song et al.28 replicated the findings of Ieda et al.25 with GMT, and
demonstrated that the addition of a bHLH domain-containing transcription factor, Hand2,
could increase the efficiency of cardiac reprogramming in vitro. Hand2 was initially
discovered in a search for a cardiac MyoD-like bHLH protein62, and is essential for a subset
of cardiac progenitors63-65, but not sufficient to induce the cardiac phenotype. Importantly,
Song et al. also showed direct conversion from non-myocyte to myocytes in vivo by
retrovirally transducing fibroblasts with GMT plus Hand2 (GHMT) into hearts after
coronary ligation. These in vivo induced cardiac-like myocytes were similar to the
endogenous cardiomyocytes, based on their gene expression, sarcomere structure and
electrophysiological features. Lineage tracing with Fsp1-Cre, an inducible Tcf21-iCre, and
αMHC-MerCreMer demonstrated the origin of the induced cardiomyocyte-like cells was
likely cardiac fibroblasts. This observation was further supported by the evidence that the
genetically pre-labeled old myocyte pool was diluted by these newly born myocyte-like
cells. Along with the emergence of new cardiomyocyte-like cells, improved heart function
and reduced scar size were observed.
A third successful example of in vivo cardiac reprogramming was reported by Inagawa et
al30. The authors used the same GMT cocktail and retroviral delivery method. Different
from Qian et al and Song et al, immunosuppressed mice were used in an attempt to promote
the survival of viral transduced cells. Reprogramming with these nude mice resulted in more
iCMs with well-defined sarcomere structure. Furthermore, in order to improve the
transduction of GMT in vivo, Inagawa et al generated a polycistronic retrovirus expressing
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GMT at near equimolar levels from the same promoter using “self-cleaving” 2A peptides
that resulted in a better reprogramming efficiency. Although the global outcome of GMT
introduction in this system was not clear, use of a 2A polycistronic vector and
immunosuppressed mice further refined the in vivo reprogramming technology.
These three studies provide compelling evidence that the abundant non-myocyte pool in the
heart, largely composed of fibroblasts, can be transdifferentiated into new cardiomyocyte-
like cells in vivo after injury, resulting in regeneration of myocardium and improved cardiac
function. The functional improvement can be partially explained by new myocytes that
increase force generation, but a fundamental alteration in the nature of scar-producing
fibroblasts could also account for part of the reduction in scar size and improvement of
cardiac output.
Alternative strategies for cardiac reprogramming
The strategy involving serial deletion of one factor at a time can yield potential
combinations of factors for reprogramming but, due to the complex interactions between
networks, may not necessarily yield the optimal combination. To address this, Protze et al.66
screened 120 triplet combinations of 10 important developmental cardiac transcription
factors expressed by lentiviruses in mouse embryonic fibroblasts (MEFs) for their ability to
induce a myocyte-like phenotype. Rather than measuring the activation of a single reporter,
they assayed expression of a panel of cardiac genes by qPCR. In this screen, Myocardin,
Mef2c and Tbx5 were the optimal combination to convert fibroblasts into myocyte-like
cells, determined by gene expression, sarcomere formation and ion channel activity,
suggesting multiple combinations may exist for efficient cardiac reprogramming. Protze et
al. also performed a time-course experiment and showed a progressive process involved in
direct cardiac reprogramming in which a more complete cardiac phenotype arose over time.
miRNAs have important roles in cardiomyocyte decisions and are often regulated by the
major cardiac transcription factors and, in turn, titrate the dosage of the key transcriptional
networks54, 67. In particular, miR-1, the most abundant cardiac miRNA, promotes muscle
gene expression and regulates many aspects of cardiac biology68-71. Recently, Jayawardena
et al. showed that a combination of four muscle-specific miRNAs (miR-1, miR-133,
miR-208, miR-499) was sufficient to transdifferentiate mouse fibroblasts into
cardiomyocyte-like cells in vitro and in vivo. Remarkably, in the presence of a JAK-1
inhibitor, miR-1 alone was sufficient to reprogram the cardiac fibroblasts29.
While many groups have now successfully reprogrammed fibroblasts to cardiomyocyte-like
cells in vitro, others have struggled72, highlighting the challenges to easily mastering this
technique. The use of fresh, non-senescing fibroblasts, high titers of viruses expressing the
reprogramming factors, and careful culture conditions are among the variables involved in
achieving successful reprogramming73. Future work on standardizing the conditions and
improving the conversion efficiency in vitro will be necessary to make this a routine
procedure in many other laboratories.
Challenges and future directions
Despite the excitement and potential of direct cardiac reprogramming technology, several
challenges remain, as would be expected for any new technology. All of the work thus far
has been performed in rodents. It will be intriguing to determine if human fibroblasts can be
similarly reprogrammed into iCMs. Although this might be technically challenging,
identification of additional factors or a different combination of factors might allow
conversion to occur in human fibroblasts given the success in human neuronal and iPSC
reprogramming. Recently, successful reprogramming of human fibroblasts to an early
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cardiac progenitor state was reported using the transcription factors, MESP1 and ETS-152.
The cardiac progenitors were multipotent and could subsequently differentiate into
myocytes with calcium transients. However, direct reprogramming to a human adult-like
cardiomyocyte, bypassing the embryonic stage, has not yet been reported. In addition,
preclinical trials on large animal models, such as pigs, should be rigorously performed with
careful monitoring of potential side effects, especially the risk of arrhythmias. Finally, new
non-integrating methods for delivery of reprogramming factors and methods to increase
efficiency will be important.
The low conversion rate of fibroblasts to fully reprogrammed iCMs in vitro is a major
challenge for deciphering the mechanism of reprogramming. The relative inefficiency in
vitro is not surprising, considering the iPSC reprogramming efficiency rate (0.01–0.1%),
which is likely due to major epigenetic barriers that cells cannot easily overcome74. Unlike
iPSCs, reprogrammed cardiomyocytes rapidly exit the cell cycle, making efficiency a much
bigger concern. Understanding how progressive epigenetic and transcriptional changes
occur temporally during direct cardiac reprogramming is an important first step towards
overcoming these hurdles. As highlighted from two recent genome-wide epigenetic studies
of ESC-derived CMs75, 76, temporal alterations in chromatin structure patterns lead to
activation of key genes associated with heart development and function at distinctive
differentiation stages. Such mechanisms might be informative for cardiac reprogramming.
Second, methods aiming to improve delivery efficiency, such as the utilization of a
polycistronic vector30 to control for homogenous reprogramming gene expression, nano-
particle techniques for specific and efficient targeting, immunosuppression to promote
survival of transduced cells30, and the administration of Thymosin β4 to mobilize and
activate fibroblasts60, may increase the final number of reprogrammed iCMs. Third,
techniques that enhance the maturation of cardiomyocytes should be used to promote the
progression of iCMs from immature to mature stages. These include supplying the cells with
cytokines at defined stages, altering the expression pattern of certain ion channel regulators,
exposing cells to mechanical forces and providing extracellular matrix and/or endothelial
cells. Last, small-molecule and secreted factor screens geared towards increasing iCM
numbers and quality should be performed to identify externally administered factors that
promote the reprogramming process.
Approaches to improve efficiency in vitro will aid in mechanistic understanding of the
reprogramming process and may ultimately allow use of direct reprogramming to model
human disease. Although current technology does not generate sufficient numbers of fully
reprogrammed iCMs for disease modeling studies, improvements in efficiency will be
valuable since iCMs appear to achieve electrical maturation that is more similar to
ventricular myocytes, particularly when reprogrammed in vivo, and this has been difficult to
achieve with ESC- or iPSC-derived cardiomyocytes. Generation of sufficient numbers of
fully reprogrammed cells in vitro would also be valuable for drug toxicity studies and drug
screening.
In contrast, current iCM technology is quite efficient for in vivo reprogramming. Thus,
harnessing the vast endogenous pool of non-cardiomyocytes seems like a viable approach to
regenerate heart muscle without cell-based therapy. Although this would require a gene
therapy approach ideally using non-integration vectors such as adeno-associated viral
(AAV) vectors, a reasonable regulatory path exists for virally mediated gene delivery with
scores of FDA-approved trials underway and the recent approval of a gene therapy drug for
lipoprotein lipase deficiency in Europe. Future identification of small molecules or secreted
proteins that could replace each transcription factor, as has been done for iPSC
reprogramming77, may allow an alternative to gene therapy. It is possible that in vivo
reprogramming of cells to regenerate damaged tissue will serve as a new paradigm for many
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human diseases, and the lessons learned in the cardiac area will be applicable to strategies to
realize this dream in other tissues. While many challenges lie ahead in advancing this
nascent technology, the opportunities and the potential benefits are significant, and we are
confident the field will continue to push this technology further in the years ahead.
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Figure 1. Approaches to direct cardiac reprogramming
Several methods for converting non-myocytes to cardiomyocyte-like cells have been
published and are summarized here. In the first example, injection of factors into the non-
cardiogenic mesoderm of E7.0 embryos resulted in ectopic beating cells (E8.5 embryos
shown for simplicity). In vitro delivery of various cocktails resulted in primarily partially
reprogrammed cells, while in vivo delivery yielded more fully reprogrammed
cardiomyocyte-like cells.
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Figure 2. Direct conversion of cardiac fibroblasts into cardiomyocyte-like cells in vivo
Masson-Trichrome (left panel) and immunofluorescent staining for α-Actinin and βGal
(right panels) in GMT injected Periostin-Cre:R26R-lacZ mouse heart 4 weeks post-coronary
ligation. Scale bars: 500 μm in the left panel, 50 μm in the right two panels.
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